TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04188145
Drug: Fluoropyrimidine
Normalized name: Fluoropyrimidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15).
Study: NCT01975454
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
Study: NCT01975454
Drug: Herbal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLBZT based herbal decoction administered orally twice a day
Study: NCT00273455
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02004613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administration matching dexmedetomidine rate of infusion
Study: NCT02327078
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT00984282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
Study: NCT02687646
Drug: Adult Allogeneic Mesenchymal cells from adipose tissue.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg
Study: NCT01520298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
Study: NCT01520298
Drug: Acetaminophen IV
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
Study: NCT00414128
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
Study: NCT04329832
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
Study: NCT00990106
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06168188
Drug: Neulasta® (pegfilgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of Neulasta® (pegfilgrastim) after TON
Study: NCT04729764
Drug: GP681 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.
Study: NCT00979771
Drug: GSK706769
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg GSK706769 twice daily orally (BID) for 28 days
Study: NCT00979771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK706769 matched-placebo twice daily orally (BID) for 28 days
Study: NCT01223183
Drug: hypertonic saline (7%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single treatment by inhalation
Study: NCT01223183
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: single treatment by inhalation
Study: NCT02605421
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.
Study: NCT01360190
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluoxetine 20 mg. daily
Study: NCT01769781
Drug: GnRH analog alone
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment for three months with GnRH analog (leuprolide acetate) alone
Study: NCT00370565
Drug: Inhaled Human Insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03688828
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg bid
Study: NCT02457312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
Study: NCT02601651
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
Study: NCT00648557
Drug: Levothyroxine Sodium Tablets 200 mg
Normalized name: levothyroxine sodium Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x200mcg, single dose fasting
Study: NCT00648557
Drug: Synthroid Tablets 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x200mcg, single dose fasting
Study: NCT03451123
Drug: FET PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FET PET/MRI scan before and after surgery
Study: NCT03274856
Drug: GLWL-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 3 capsules, twice a day
Study: NCT03274856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 3 capsules, twice a day
Study: NCT03688828
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5g bid
Study: NCT00948428
Drug: Aldara™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
Study: NCT00948428
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
Study: NCT00463619
Drug: Retarded release phosphatidylcholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g phosphatidylcholine, given QTD
Study: NCT02290041
Drug: Infusion of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of placebo (weeks 0-4-8-20)
Study: NCT04096287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose
Study: NCT01495195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: microcrystalline cellulose
Study: NCT02814175
Drug: methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03084601
Drug: Calcium Hydroxide, Iodoform, paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: mixture of calcium hydroxide and iodoform
Study: NCT03084601
Drug: 3-mixtatin
Normalized name: HISTATIN 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin
Study: NCT00413296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, Tablets, no active ingredient in the tablets, (1-6tablets/day)for 12 wks in the 2nd phase of the study.
Study: NCT03349684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose matching placebo, oral
Study: NCT01772056
Drug: Placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group: on treatment with twice weekly on consecutive days vehicle cream for 16 weeks or at relapse.
Study: NCT01118689
Drug: MLN0128
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN0128 administered orally once daily for 28 days
Study: NCT04463264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet every 6 hours for 14 days) orally with food (P.O.).
Study: NCT01913002
Drug: LX4211 800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01913002
Drug: LX4211 2000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01913002
Drug: LX4211 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00656864
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02744196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution will look identical to the Acellbia solution.
Study: NCT02744196
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01462617
Drug: GSK2269557
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT02767128
Drug: Shohl's solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01462617
Drug: GSK2269557 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT00303485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po monthly for 6 months
Study: NCT00303485
Drug: Vitamin D and calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00303485
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg po monthly for 6 months
Study: NCT01235234
Drug: CF101
Normalized name: CF101
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally q12h
Study: NCT00597688
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mucosal application of placebo gel
Study: NCT04173845
Drug: Tianqi Pingchan Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianqi Pingchan Granule are given twice a day
Study: NCT04173845
Drug: Tianqi Pingchan Granule Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianqi Pingchan Granule Placebo
Study: NCT03686384
Drug: SVT-15652
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vial twice daily
Study: NCT03686384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vial twice daily
Study: NCT00390039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN Placebo q1h PRN
Study: NCT00390039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Placebo q3h PRN
Study: NCT00390039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN Placebo q3h PRN
Study: NCT03536559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is liquid with identical color and taste
Study: NCT01770236
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
Study: NCT01052506
Drug: BIIB033
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
Study: NCT01052506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
Study: NCT00374387
Drug: minipill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00811681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a placebo administered orally once a day after the first visit and for a total of 2 years.
Study: NCT04780412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal placebo pills given 90-120 minutes before an elective caesarian section.
Study: NCT00197899
Drug: E. Coli endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03425539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
Study: NCT02040844
Drug: Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02265718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 - matching tablet taken once on Day 0 and once on Day 28
Study: NCT00629811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.~Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.~Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug.
Study: NCT00477412
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00477412
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00477412
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04244591
Drug: methylprednisolone therapy
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 40 mg q12h for 5 days
Study: NCT00237341
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01620814
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00186810
Drug: Busulfan, Cyclophosphamide, Horse ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.
Study: NCT01268761
Drug: Placebo (saline solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
Study: NCT02977533
Drug: GZ402668
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02977533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02540070
Drug: epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02540070
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00432887
Drug: caffeine administration
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03736161
Drug: Group B- Methotrexate
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B patients will receive Methotrexate in increasing dose weekly with maximum dose up to 25 mg/week. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
Study: NCT02640820
Drug: Sensitizing DPCP Ointment
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensitization
Study: NCT02640820
Drug: Treatment DPCP Ointment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment
Study: NCT01322048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV q6h and Per Tube q12, both for 7 days
Study: NCT02627989
Drug: Diflucortolone valerate (Nerisona)
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
Study: NCT02627989
Drug: Diflucortolone valerate (Texmeten)
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
Study: NCT02792153
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
Study: NCT03781505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ropivacaine
Study: NCT03722524
Drug: amlodipine / indapamide / perindopril arginine FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB / diuretic / ACE inhibitor
Study: NCT02794519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
Study: NCT02794519
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
Study: NCT01679795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01001923
Drug: Placebo (for REGN475/SAR164877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes
Study: NCT04543695
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.~6 courses，3 weeks per course
Study: NCT04543695
Drug: mFOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.
Study: NCT02638168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inert placebo ingredient
Study: NCT00475904
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo cream and caps
Study: NCT01090440
Drug: GSK1144814
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
Study: NCT02663830
Drug: clomiphene only
Normalized name: Clomiphene only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
Study: NCT01529034
Drug: USL261
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03305068
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00142051
Drug: nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 ppm 8 hrs, 40 ppm 8 hrs, 20 ppm 4 hrs, 10 ppm 4 hrs
Study: NCT01708122
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mcg in 1 mL intranasal spray
Study: NCT00440804
Drug: ibuprofen l-lysine iv solution (NeoProfen (R) )
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04348032
Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive PLD and apatinib at the same time. The dose of intravenous chemotherapy drug is calculated according to the body surface area, and the dose of oral drug apatinib is 250mg qd. Dose suspension and dose reduction are allowed only when patients have serious adverse reactions. The intravenous chemotherapy drug PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%), and the oral drug apatinib dose is only allowed to be reduced once (250mg gravity QD changed to 250mg gravity Qod). Otherwise the patients will drop out of the study.
Study: NCT04348032
Drug: PLD 40mg/m2 ivgtt q4w
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of intravenous chemotherapy drug is calculated according to the body surface area. When patients have serious adverse reactions, dose suspension and dose reduction are allowed. The PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%).
Study: NCT00479856
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy